Abstract
The angiotensin-converting enzyme-2 (ACE-2) alters the pathophysiology of various fatal cardiovascular diseases, including ischemic heart disease, whereas angiotensin 1-7 (Ang 1–7) exerts a wide range of actions. The effects of ischemia-reperfusion (IR) injury include damage to myocardial tissue that initiates protease action, causing cardiac cell death. Angiotensin- II (Ang-II) contributes through the renin-angiotensin system (RAS) to the IR injury, whereas Ang 1–7 paradoxically exerts a protective effect through the same. Thus, the myocardial ischemic reperfusion injury (MIRI) may be altered by the RAS of the heart. This review paper focuses on ACE-2, angiotensin-converting enzyme (ACE), and Ang 1–7 regulation in the RAS of the heart in the pathophysiology of MIRI. The treatment in such conditions using ACE-2 activator, ACE inhibitor, and Ang-II antagonists may promote vascular functions as well as cardio- protection.
Keywords: Heart, renin-angiotensin system, myocardial ischemia-reperfusion injury, ACE-2 activator, ACE inhibitor, angiotensin-II antagonist.
Current Drug Research Reviews
Title:Modulation of Angiotensin-II and Angiotensin 1-7 Levels Influences Cardiac Function in Myocardial Ischemia-reperfusion Injury
Volume: 17 Issue: 1
Author(s): Prabhat Kumar Upadhyay, Navneet Thakur, Vishal Kumar Vishwakarma*, Hridaya Shankar Chaurasiya and Tarique Mahmood Ansari
Affiliation:
- Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India
Keywords: Heart, renin-angiotensin system, myocardial ischemia-reperfusion injury, ACE-2 activator, ACE inhibitor, angiotensin-II antagonist.
Abstract: The angiotensin-converting enzyme-2 (ACE-2) alters the pathophysiology of various fatal cardiovascular diseases, including ischemic heart disease, whereas angiotensin 1-7 (Ang 1–7) exerts a wide range of actions. The effects of ischemia-reperfusion (IR) injury include damage to myocardial tissue that initiates protease action, causing cardiac cell death. Angiotensin- II (Ang-II) contributes through the renin-angiotensin system (RAS) to the IR injury, whereas Ang 1–7 paradoxically exerts a protective effect through the same. Thus, the myocardial ischemic reperfusion injury (MIRI) may be altered by the RAS of the heart. This review paper focuses on ACE-2, angiotensin-converting enzyme (ACE), and Ang 1–7 regulation in the RAS of the heart in the pathophysiology of MIRI. The treatment in such conditions using ACE-2 activator, ACE inhibitor, and Ang-II antagonists may promote vascular functions as well as cardio- protection.
Export Options
About this article
Cite this article as:
Upadhyay Kumar Prabhat, Thakur Navneet, Vishwakarma Kumar Vishal*, Chaurasiya Shankar Hridaya and Ansari Mahmood Tarique, Modulation of Angiotensin-II and Angiotensin 1-7 Levels Influences Cardiac Function in Myocardial Ischemia-reperfusion Injury, Current Drug Research Reviews 2025; 17 (1) . https://dx.doi.org/10.2174/0125899775280160240122065607
DOI https://dx.doi.org/10.2174/0125899775280160240122065607 |
Print ISSN 2589-9775 |
Publisher Name Bentham Science Publisher |
Online ISSN 2589-9783 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Validated Chiral-RP-UPLC-MS/MS Method for the Enantiomeric Detection of Rivaroxaban <i>In vitro</i>
Current Pharmaceutical Analysis Micronutrient Biofortification in Rice through New Breeding Techniques (NBTs): Bangladesh Perspective
Current Nutraceuticals The Multimodal Treatment of Acromegaly: Current Status and Future Perspectives
Endocrine, Metabolic & Immune Disorders - Drug Targets Structure-Activity Relationship Studies on ADAM Protein-Integrin Interactions
Cardiovascular & Hematological Agents in Medicinal Chemistry COX-2 Inhibitors and Cardiovascular Events: Deja Vu Du Jour
Vascular Disease Prevention (Discontinued) PEGylation: a successful approach to improve the biopharmaceutical potential of snake venom thrombin-like serine protease
Protein & Peptide Letters The Concept of “Neuroprotection” in Neurological Diseases
Current Neuropharmacology From Physiome to Pathome: A Systems Biology Model of Major Depressive Disorder and the Psycho-Immune-Neuroendocrine Network
Current Psychiatry Reviews Meet Our Editorial Board Member
Current Vascular Pharmacology Metabolism-Directed Optimisation of Antithrombotics: The Prodrug Principle
Current Pharmaceutical Design Circadian Variation of Cardiovascular Events and Morning Blood Pressure Surge
Vascular Disease Prevention (Discontinued) Thymosin β4 Protein Therapy for Cardiac Repair
Current Pharmaceutical Design Older Adults with Amnestic Mild Cognitive Impairment Exhibit Exacerbated Gait Slowing under Dual-Task Challenges
Current Alzheimer Research Cell Death Mechanisms in Stroke and Novel Molecular and Cellular Treatment Options
Current Neuropharmacology Membrane and Soluble Forms of Endoglin in Preeclampsia
Current Molecular Medicine Currently Used Biologic Agents in the Management of Behcet’s Syndrome
Current Medicinal Chemistry Relationship Between the Chemokine Receptor CCR5 and Microglia in Neurological Disorders: Consequences of Targeting CCR5 on Neuroinflammation, Neuronal Death and Regeneration in a Model of Epilepsy
CNS & Neurological Disorders - Drug Targets Mechanisms and Treatments of Oxidative Stress in Atrial Fibrillation
Current Pharmaceutical Design Ionotropic Glutamate Receptor Biology: Effect on Synaptic Connectivity and Function in Neurological Disease
Current Medicinal Chemistry Prediction of Drug-Drug Interactions Arising From Mechanism-Based Inactivation: Key Input Parameters and Impact on Risk Assessment
Current Drug Metabolism